Key facts
- This page summarizes NOVARTIS AG's Form 3 filing for Tourmaline Bio, Inc. (TRML).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Oct 2025, 12:12.
NOVARTIS AG - 28 Oct 2025 Form 3 Insider Report for Tourmaline Bio, Inc. (TRML)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TRML
- Reported as of
- 28 Oct 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jonathan Emery As Attorney
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
NOVARTIS AG filed Form 3 for Tourmaline Bio, Inc. (TRML) on 28 Oct 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001114448
Primary reporting owner
NOVARTIS AG
- Relationship
- 10%+ Owner
- Address
- LICHTSTRASSE 35, BASEL, SWITZERLAND
- Signature
- /s/ Jonathan Emery As Attorney
- Signature date
- 28 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRML
holding
Common Stock, par value $0.0001
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,030,382
- Date
- 28 Oct 2025
- Ownership
- See Footnote
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These shares are owned directly by Torino Merger Sub Inc., an indirect wholly-owned subsidiary of Novartis AG.